Market Access

In today’s Pharma Pulse, Walgreens reshapes pharmacist roles, pharmacies expand injectable access, GoodRx and Eli Lilly broaden GLP-1 access, radiopharma investment grows, and AbbVie signs a $745 million Haisco licensing deal.

Roel van den Akker evaluates how blockbuster GLP-1s may shift broader commercialization trends.

Lilly's Foundayo and Zepbound KwikPen are now available on GoodRx for self-pay access.

In this week’s Pharma Pulse, tariffs reshape drug supply, a fragile ceasefire tests global pharma, Wegovy goes higher-dose, and patients still can't get appointments fast enough.

Laura Blair discusses how DTP models make manufacturers rethink traditional access and distribution strategies.

Manasi Salgaonkar examines how accurate class of trade research enables precise pricing, contract eligibility, and compliance.

Anthony Bianciella explains how rare disease brands lose patients because journey maps prioritize prescribing intent over the complex, unfamiliar logistics of post-diagnosis access.

Eli Lilly’s newest GLP-1, Foundayo (orforglipron), is the first FDA-approved weight loss pill that can be taken without food or water restrictions.

Amber Hussain-Siddique says operational discipline in inventory and logistics is the vital, yet overlooked, key to sustaining low-cost generic drug supplies in the U.S.

To fix America's drug shortages, pharma must look beyond manufacturing and overhaul how medicines are allocated and delivered to smaller hospitals.

Pharma can optimize DTP strategies by leveraging data on affordability and patient behavior.

In today's Pharma Pulse, the FDA flags misleading promotional claims from ImmunityBio regarding its cancer therapy and MedImpact launches new solutions to address the skyrocketing employer costs of GLP-1 weight management therapies.

New Benefit 360 and Direct Fund models aim to bridge the gap between clinical eligibility and employer-sponsored coverage.

Workflow alignment, e-prescribing integration, and behavior change strategies are critical to reducing friction across the direct-to-patient ecosystem.

In today's Pharma Pulse, the FDA grants expanded approval for Imcivree, while new research highlights how optimizing pharmacy technician roles can significantly boost vaccine access and uptake.

Jordan Armstrong outlines how adaptable DTP programs can reduce barriers and accelerate patient access to therapy.

In today’s Pharma Pulse, the FDA expands a key biologic approval for pediatric patients, and new research highlights the success of pharmacist-led testing in rural communities.

Kroger will offer the Zepbound KwikPen at its participating retail pharmacies.

In today’s Pharma Pulse, Eli Lilly issues a safety warning and SteinCares enters a licensing agreement with Shilpa Biologicals to expand biosimilar access in Latin America.

In today’s Pharma Pulse, the FDA launched a unified monitoring system to enable real-time adverse event reporting, and direct-to-employer drug purchasing models are emerging as companies look to bypass traditional intermediaries.

In today’s Pharma Pulse, the FDA approved Wellcovorin as the first therapy for an ultra-rare neurological disorder, and disparities in OTC naloxone access persist despite declining retail prices.

Hims & Hers will offer branded semaglutide instead of compounded GLP-1 drugs.

In today's Pharma Pulse, Ipsen voluntarily withdraws tazemetostat due to safety signals, while the FDA approves deucravacitinib for active psoriatic arthritis.